(Q24234454)

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

Temporal trends in the incidence of multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

Validation of the functional assessment of multiple sclerosis quality of life instrument

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

Complement activation determines the therapeutic activity of rituximab in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

Increasing prevalence and incidence of multiple sclerosis in South East Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

Epidemiology of multiple sclerosis in Europe: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

The immunopathology of multiple sclerosis: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

Evidence for a two-stage disability progression in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

Economic burden of multiple sclerosis: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

7 January 2021

inferred from DOI database lookup

Surrogate endpoints for EDSS worsening in multiple sclerosis: A meta-analytic approach

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

7 January 2021

inferred from DOI database lookup

Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: relations between study investigators, advisors, and sponsors. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB2

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD009130.PUB2

0 references

Fatcat ID

release_4yyzyk63rngv5plxisdoor5nsu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4yyzyk63rngv5plxisdoor5nsu

24 November 2022